Anemia, Bone Mineral, and Comorbidities
Key Takeaways
Renal anemia results primarily from decreased erythropoietin production; iron studies (ferritin, TSAT) guide therapy alongside ESAs.
CKD-MBD involves phosphate retention, calcium imbalance, and secondary hyperparathyroidism — KDIGO targets guide nursing education and monitoring.
Phosphate binders must be taken with meals; non-calcium binders are preferred when calcium or Ca×P product is elevated.
Diabetes and cardiovascular disease are the dominant CKD comorbidities; glycemic and blood pressure control affect progression and dialysis outcomes.
Malnutrition-inflammation complex lowers albumin and confounds nutritional assessment — look at trend, nPCR, and clinical intake.
Anemia, Bone Mineral, and Comorbidities
Quick Answer: Renal anemia follows EPO deficiency plus iron restriction; treat with iron repletion and erythropoiesis-stimulating agents (ESAs) per protocol. CKD-mineral and bone disorder (CKD-MBD) means high phosphate, abnormal calcium, and elevated PTH — nurses teach binder timing and monitor Ca×P product. Diabetes and cardiovascular disease drive most dialysis morbidity.
These complications explain why dialysis patients feel exhausted, itch, fracture bones, and die from cardiovascular events. CDN Domain 1 items test nursing monitoring, patient teaching, and when lab trends require nephrology/pharmacy follow-up.
Renal Anemia Pathophysiology
As GFR falls, peritubular fibroblasts produce less erythropoietin (EPO). Anemia develops gradually:
| Stage | Typical hemoglobin trend | Symptoms |
|---|---|---|
| CKD G3–G4 | Hgb drifts toward 10–11 g/dL | Fatigue, decreased exercise tolerance |
| Dialysis | Often target 10–11 g/dL per facility/KDIGO-influenced policy | Dyspnea, angina worsening, cognitive slowing |
Iron deficiency worsens ESA resistance. Monitor:
| Test | Dialysis nursing interpretation |
|---|---|
| Ferritin | Iron stores; very high may reflect inflammation |
| TSAT (transferrin saturation) | Functional iron availability; low TSAT limits EPO response |
| Hgb/Hct | Trend more important than single value |
ESA therapy (epoetin alfa, darbepoetin) requires monitoring blood pressure — hypertension can worsen. IV iron is common in HD because ongoing blood loss in the circuit and inflammation increase iron needs.
Exam trap: Transfuse aggressively to Hgb >12 without indication — KDIGO-era practice favors ESA + iron with cautious transfusion because higher Hgb targets increased cardiovascular risk in trials.
CKD-MBD: Phosphate, Calcium, PTH
CKD-MBD is the spectrum of biochemical, bone, and vascular abnormalities from failing phosphate excretion and disturbed vitamin D metabolism.
| Parameter | Common dialysis target range (KDIGO-influenced) | Nursing focus |
|---|---|---|
| Phosphorus | ~3.5–5.5 mg/dL | Diet, binders, adherence |
| Corrected calcium | ~8.4–10.2 mg/dL | Avoid hypercalcemia with calcium-based binders |
| iPTH | Roughly 2–9× upper limit normal on dialysis | Secondary hyperparathyroidism management |
| Ca×P product | Keep <55 mg²/dL² | Vascular calcification risk when elevated |
Secondary hyperparathyroidism develops when high phosphate and low active vitamin D stimulate PTH secretion. Severe disease causes renal osteodystrophy — bone pain, fractures, and vascular calcification.
Phosphate Binders and Nursing Teaching
| Binder class | Examples | Key teaching |
|---|---|---|
| Calcium-based | Calcium acetate, calcium carbonate | Cheap; risk hypercalcemia when Ca already high |
| Non-calcium | Sevelamer, lanthanum | Preferred when Ca or Ca×P elevated |
| Iron-based | Ferric citrate, sucroferric oxyhydroxide | Dual phosphate and iron benefit |
Critical teaching point: binders work only when taken with the first bite of food containing phosphate. Binders taken 30 minutes before meals bind little dietary phosphate — a favorite CDN item.
Dietary counseling targets phosphate additives (processed meats, colas with phosphoric acid) — organic phosphorus in plants is less absorbed.
Vitamin D and Calcimimetics (Nursing Awareness)
Nephrologists prescribe active vitamin D analogs (calcitriol, paricalcitol) to suppress PTH. Nurses watch for hypercalcemia and hyperphosphatemia worsening. Calcimimetics (cinacalcet) lower PTH by sensitizing the calcium-sensing receptor — monitor for hypocalcemia and nausea.
You are not expected to select drug doses on CDN — you recognize side effects, lab trends, and patient education needs.
Diabetes and Cardiovascular Comorbidity
Most U.S. dialysis patients have diabetes and/or hypertension. Nursing implications:
| Comorbidity | Dialysis-specific concern |
|---|---|
| Diabetes | Glycemic variability with meals, dialysate glucose (PD), foot care with neuropathy |
| Hypertension | Volume-dependent BP — address dry weight and sodium |
| CAD/heart failure | UF goals, ischemia during HD hypotension, careful fluid removal |
| Peripheral vascular disease | AV access surveillance, wound healing |
Malnutrition-inflammation syndrome lowers serum albumin independent of intake. Use dietary recall, SGA, nPCR, and handgrip when available — do not blame patients solely for low albumin.
Worked Exam Scenario
A HD patient has phosphorus 7.2 mg/dL, corrected calcium 10.3 mg/dL, Ca×P 74, and takes calcium acetate inconsistently before meals (often 30 minutes early). Which nursing plan is highest priority?
Plan: Teach binder timing with first bite; coordinate with nephrologist to switch from calcium-based to non-calcium binder given hypercalcemia and elevated Ca×P; reinforce low-phosphate diet including additive avoidance; recheck labs per protocol. Increasing calcium acetate would worsen hypercalcemia.
Common CDN Traps
- Binder timing errors in answer choices
- Assuming low albumin always means poor diet (inflammation matters)
- Targeting Hgb >12 as default ESA goal
- Ignoring Ca×P product when only phosphorus is listed
Study Routine
- Memorize Ca×P calculation (multiply Ca × phos)
- State ferritin/TSAT roles in one sentence each
- List three high-phosphate foods and three additive sources
Final Check
Explain renal anemia mechanism, binder timing rule, and when non-calcium binders are preferred — without notes.
Inflammation and Functional Iron Deficiency
Chronic inflammation elevates hepcidin, lowering TSAT despite ferritin that appears adequate. Pattern: ferritin >500 ng/mL with TSAT <20% may reflect inflammation — follow nephrology protocol rather than reflexively stopping iron. Reassess anemia management after hospitalization or access infection when inflammation spikes.
Cardiovascular Risk Reduction Nursing
CKD is a coronary disease equivalent in risk stratification. Nursing contributions tested on CDN:
- Blood pressure at goal before and after dialysis — avoid both uncontrolled HTN and intradialytic hypotension
- Smoking cessation referral and statin adherence when prescribed
- Dialysis dose and access function — inadequate clearance worsens uremic cardiomyopathy
- Volume control — chronic overload strains LV function
When a stem pairs low Hgb with high ferritin and low TSAT, think functional iron deficiency with inflammation before selecting transfusion.
A hemodialysis patient has hemoglobin 9.2 g/dL, ferritin 150 ng/mL, and TSAT 18%. The nephrologist plans anemia management. Which factor most limits erythropoiesis-stimulating agent effectiveness in this profile?
Excess iron storage with ferritin above 100
Functional iron deficiency suggested by low transferrin saturation despite moderate ferritin
Hyperphosphatemia directly blocking erythropoietin receptors
Normal hemoglobin for dialysis patients requiring no action
A patient takes sevelamer carbonate but swallows all doses on an empty stomach 30 minutes before meals for fewer GI side effects. Phosphorus remains 6.9 mg/dL. What is the best nursing intervention?
Continue empty-stomach dosing because sevelamer absorption is better fasting
Stop all phosphate binders because they never work in dialysis
Teach the patient to take sevelamer with the first bite of meals so the binder contacts dietary phosphate
Replace sevelamer with oral calcium carbonate taken at bedtime only
Which laboratory combination most strongly signals elevated vascular calcification risk requiring coordinated nephrology and dietary follow-up?
Phosphorus 4.0 mg/dL and calcium 9.2 mg/dL
Hemoglobin 10.5 g/dL and ferritin 400 ng/mL
Sodium 138 mEq/L and potassium 4.2 mEq/L
Corrected calcium 10.6 mg/dL, phosphorus 7.0 mg/dL, and calcium–phosphorus product above 55 mg²/dL²
Sections you finish are checked off in the contents.